Evidence map›Paper›PMID 39469848›Full record

ArticleNanomedicine (London, England)2025

Pluronic F127/lecithin PLGA nanoparticles as carriers of monocyte-targeted jakinibs: a potential therapeutic platform.

Karen Álvarez, Jennifer T Cruz, Luis F Giraldo, Víctor H Orozco, Gloria Vásquez, Mauricio Rojas-López

Abstract read
In one paragraph

Article in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Regulatory Effects of CD14Journal of immunology research · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Karen ÁlvarezCellular Immunology & Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-1968-4647
Jennifer T CruzPolymer Research Laboratory, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-2800-4973
Luis F GiraldoPolymer Research Laboratory, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-6982-3916
Víctor H OrozcoPolymer Research Laboratory, University of Antioquia, Medellin, Colombia.ORCID 0000-0001-5296-247X
Gloria VásquezCellular Immunology & Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-0647-0906
Mauricio Rojas-LópezCellular Immunology & Immunogenetics Group (GICIG), Faculty of Medicine, University of Antioquia, Medellin, Colombia.ORCID 0000-0002-7791-9328

Funding

Ministerio de Ciencia, Tecnología e Innovación 111584467267-925-2019
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Drug CarriersMonocytesNanoparticlesPoloxamerPolylactic Acid-Polyglycolic Acid CopolymerCell ProliferationCytokinesHumansJanus Kinase 1Janus Kinase InhibitorsPiperidinesCytokinesDrug CarriersJAK1 protein, humanJanus Kinase 1Janus Kinase InhibitorsPiperidinesPoloxamerPolylactic Acid-Polyglycolic Acid CopolymerjakinibsJAK-STAT pathwayL-lactic-co-glycolic acidmonocytesnanoparticles

Identifiers

PMID39469848
PMCPMC11730121

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.